Filana Therapeutics, Inc. (FLNA) Balance Sheet

The consistent reduction in total assets reflects the non-discretionary nature of R&D spending in the absence of commercial revenue. Investors should monitor this trajectory, as the diminishing asset base limits the company's financial flexibility to navigate potential regulatory delays or unexpected legal costs.

While a current ratio of 2.27 suggests the company maintains sufficient short-term liquidity to meet current obligations, the rapid decline in cash from $207.3 million in 2024Q2 to $106.1 million in 2025Q3 warrants caution. This trend suggests that the firm may face increasing pressure to secure additional financing if clinical timelines extend beyond current projections.

The significant negative retained earnings highlight the high-risk nature of the business model, where equity value is entirely dependent on future clinical success rather than current operational profitability. The erosion of equity suggests that shareholders are absorbing the full cost of the company's R&D-heavy strategy, leaving little margin for error.